The fragile X syndrome

History, diagnosis, and treatment

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The fragile X (marker X) syndrome is a relatively common form of X-linked mental retardation. The karyotypic hallmark of the syndrome consists of a pronounced constriction near the terminus of the long arm of the X chromosome (fragile site), expressed in vitro only under conditions where thymidylate production is blocked (reduced folate levels and/or addition of methotrexate or 5-fluorodeoxyuridine). Clinical features associated with the syndrome include macroorchidism, large or prominent ears, and significant emotional dysfunction. In the present review, historical, diagnostic, biochemical, and clinical aspects of this syndrome are presented. Recent anecdotal reports of clinical improvement following high dose folic acid treatment will be discussed.

Original languageEnglish (US)
Pages (from-to)122-130
Number of pages9
JournalJournal of Developmental and Behavioral Pediatrics
Volume4
Issue number2
StatePublished - 1983
Externally publishedYes

Fingerprint

Fragile X Syndrome
History
Folic Acid
Chromosome Fragile Sites
X-Linked Mental Retardation
Floxuridine
X Chromosome
Constriction
Methotrexate
Ear
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Behavioral Neuroscience
  • Psychology(all)
  • Developmental and Educational Psychology

Cite this

The fragile X syndrome : History, diagnosis, and treatment. / Hagerman, Randi J; McBogg, P.; Hagerman, Paul J.

In: Journal of Developmental and Behavioral Pediatrics, Vol. 4, No. 2, 1983, p. 122-130.

Research output: Contribution to journalArticle

@article{7a7111c2613842b18a31a2c001b717f6,
title = "The fragile X syndrome: History, diagnosis, and treatment",
abstract = "The fragile X (marker X) syndrome is a relatively common form of X-linked mental retardation. The karyotypic hallmark of the syndrome consists of a pronounced constriction near the terminus of the long arm of the X chromosome (fragile site), expressed in vitro only under conditions where thymidylate production is blocked (reduced folate levels and/or addition of methotrexate or 5-fluorodeoxyuridine). Clinical features associated with the syndrome include macroorchidism, large or prominent ears, and significant emotional dysfunction. In the present review, historical, diagnostic, biochemical, and clinical aspects of this syndrome are presented. Recent anecdotal reports of clinical improvement following high dose folic acid treatment will be discussed.",
author = "Hagerman, {Randi J} and P. McBogg and Hagerman, {Paul J}",
year = "1983",
language = "English (US)",
volume = "4",
pages = "122--130",
journal = "Journal of Developmental and Behavioral Pediatrics",
issn = "0196-206X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The fragile X syndrome

T2 - History, diagnosis, and treatment

AU - Hagerman, Randi J

AU - McBogg, P.

AU - Hagerman, Paul J

PY - 1983

Y1 - 1983

N2 - The fragile X (marker X) syndrome is a relatively common form of X-linked mental retardation. The karyotypic hallmark of the syndrome consists of a pronounced constriction near the terminus of the long arm of the X chromosome (fragile site), expressed in vitro only under conditions where thymidylate production is blocked (reduced folate levels and/or addition of methotrexate or 5-fluorodeoxyuridine). Clinical features associated with the syndrome include macroorchidism, large or prominent ears, and significant emotional dysfunction. In the present review, historical, diagnostic, biochemical, and clinical aspects of this syndrome are presented. Recent anecdotal reports of clinical improvement following high dose folic acid treatment will be discussed.

AB - The fragile X (marker X) syndrome is a relatively common form of X-linked mental retardation. The karyotypic hallmark of the syndrome consists of a pronounced constriction near the terminus of the long arm of the X chromosome (fragile site), expressed in vitro only under conditions where thymidylate production is blocked (reduced folate levels and/or addition of methotrexate or 5-fluorodeoxyuridine). Clinical features associated with the syndrome include macroorchidism, large or prominent ears, and significant emotional dysfunction. In the present review, historical, diagnostic, biochemical, and clinical aspects of this syndrome are presented. Recent anecdotal reports of clinical improvement following high dose folic acid treatment will be discussed.

UR - http://www.scopus.com/inward/record.url?scp=0020959803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020959803&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 122

EP - 130

JO - Journal of Developmental and Behavioral Pediatrics

JF - Journal of Developmental and Behavioral Pediatrics

SN - 0196-206X

IS - 2

ER -